Unit 3 – ADHD-Specific Prescribing in Integrated Patient Management
April 29, 2024 2025-11-17 8:47Unit 3 – ADHD-Specific Prescribing in Integrated Patient Management
Curriculum
- 4 Sections
- 33 Lessons
- Lifetime
Expand all sectionsCollapse all sections
- Module 1Understanding the current system - Navigating the referral pathway11
- 1.1UNIT 3 Introduction & Outline
- 1.2Module 1: Introduction & Outline
- 1.3Getting the patient ‘treatment ready’: Reviewing the Patient Journey (So Far)
- 1.4The “gift-wrapped” patient – preparing your patient for consultant review
- 1.5Writing a Great Consultant Referral Letter
- 1.6Overcoming Additional Hurdles – Third Party Verification
- 1.7Strategies for effective colleague communication
- 1.8The delegation letter you want
- 1.9Item 291 vs 296 – What’s the difference?
- 1.10Final Considerations Before Patient’s Consultant Appointment
- 1.11The Permit Application Process in Australia –
- Module 2Medications used in the treatment of ADHD5
- Module 3ADHD Medication: Treatment Approaches9
- 3.1MODULE 3: Introduction & Outline
- 3.2Goal oriented approach to dose titration
- 3.3Starting to Prescribe
- 3.4Short-Acting Psychostimulant Titration Protocol
- 3.5Vyvanse (Lis-dexamphetamine) Dose Titration
- 3.6Calculating long-lasting / slow-release methylphenidate dose equivalency
- 3.7Case Histories showing extremes of Psychostimulant doses needed
- 3.8Review: Contraindications for psychostimulant prescribing
- 3.9OVERVIEW; Patients, Medications and Legal / Regulatory Management
- Module 4Special Considerations in Prescribing Psychostimulant Medications8
- 4.1MODULE 4: Introduction & Outline
- 4.2ADHD medications and driving
- 4.3Pregnancy and ADHD
- 4.4Considerations for Domestic Travel (within Australia) and Discrepancies in state-by-state regulations
- 4.5International Travel Considerations with ADHD medications
- 4.6Sport
- 4.7Occupations
- 4.8Drug Testing In The Workplace



